Skip to main content
Evotec SE logo

Evotec SE — Investor Relations & Filings

Ticker · EVT ISIN · DE0005664809 LEI · 529900F9KI6OYITO9B12 F Professional, scientific and technical activities
Open in API
Filings indexed 1,778 across all filing types
Latest filing 2014-09-15 Director's Dealing
Country DE Germany
Listing F EVT

About Evotec SE

https://www.evotec.com/en

Evotec SE is a life science company focused on drug discovery and development in partnership with pharmaceutical and biotechnology firms. The company operates an integrated research and development value chain, utilizing proprietary technology platforms that incorporate AI-driven innovation and induced pluripotent stem cells (iPSC). Its expertise spans a wide range of therapeutic modalities, from small molecules to biotherapeutics. Through its Just – Evotec Biologics division, the company offers end-to-end solutions for the design, development, and manufacturing of biologic therapies, aiming to enhance their accessibility and affordability. Evotec employs flexible partnering models to accelerate the delivery of new treatments to patients with high efficiency and quality.

Recent filings

Filing Released Lang Actions
DGAP-DD: Evotec AG english
Director's Dealing Classification · 100% confidence The document explicitly states 'Directors’ Dealings' in the title and header. The content details a transaction ('Type of transaction: Purchase') by a person in a managerial role ('Position: Member of a managing body') involving company shares. This directly matches the definition for Director's Dealing (DIRS). The document is a notification about insider transactions.
2014-09-15 English
Evotec and the Jain Foundation expand collaboration: Start of multiple drug screening programmes
Regulatory Filings Classification · 100% confidence The document is a press release dated September 15, 2014, announcing the expansion of a collaboration between Evotec AG and the Jain Foundation regarding drug screening programs for dysferlinopathies. It contains keywords like "News Details," "DGAP-News," and discusses research progress, but explicitly states, "No financial details are disclosed." It is not a formal regulatory filing like a 10-K, a comprehensive financial report (IR), or a specific results announcement (ER). Since it is a general corporate announcement about a partnership and research milestone, and does not fit into the specific categories like M&A (TAR), Capital (CAP), or Director Dealing (DIRS), it falls best under the general regulatory announcement category, which often includes press releases about operational updates that aren't strictly financial results or governance changes. Given the options, 'Regulatory Filings' (RNS) serves as the best general category for non-standard corporate news releases distributed via services like DGAP, especially when the content is operational/partnership focused rather than financial reporting.
2014-09-15 English
Evotec and CHDI Foundation extend ongoing collaboration to fight Huntington's disease
Regulatory Filings Classification · 100% confidence The document is a press release dated September 11, 2014, announcing the extension of a collaboration between Evotec AG and CHDI Foundation regarding Huntington's disease research. It contains standard press release formatting, quotes from management, and boilerplate information about the companies involved. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a specific financial report (IR, AR). Since it is a general corporate announcement disseminated via DGAP (a service often used for regulatory news but here functioning as a press release distributor), and it doesn't fit the specific categories like M&A (TAR), Capital Change (CAP), or Director Dealing (DIRS), the most appropriate general category for a corporate news announcement that doesn't fit elsewhere is Regulatory Filings (RNS), which serves as a broad category for miscellaneous official announcements.
2014-09-11 English
Declaration of Voting Results & Voting Rights Announcements 2014
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is explicitly titled 'Voting Rights Announcements' and details a notification regarding a shareholder's voting rights crossing a specific threshold (3.0005%) on September 05, 2014, referencing Article 21 and 22 of the WpHG (German Securities Trading Act). This directly corresponds to the definition of 'Declaration of Voting Results & Voting Rights Announcements' (Code: DVA). The document is short and contains the announcement itself, not just a notice about an attached report.
2014-09-09 English
Evotec announces update on DiaPep277(R)
Regulatory Filings Classification · 100% confidence The document is labeled as an "Ad-hoc" announcement dated 8 September 2014, disseminated according to § 15 WpHG (German Securities Trading Act), which typically mandates immediate disclosure of price-sensitive information. The content details a significant event: the termination of development for a drug candidate (DiaPep277(R)) by a partner company (Hyperion) due to alleged misconduct, leading to an expected impairment charge for Evotec. This is a material corporate event announcement that does not fit the specific definitions for financial reports (10-K, IR, ER), management changes (MANG), or shareholder votes (AGM-R, DVA). Since it is a mandatory, immediate disclosure of non-standard corporate news that is price-sensitive and not covered by other specific codes (like DIRS, DIV, CAP, etc.), the most appropriate general category is Regulatory Filings (RNS), which serves as the fallback for miscellaneous regulatory announcements.
2014-09-08 English
Evotec AG: Release according to Article 26a of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a short announcement (1370 characters) titled 'Total Voting Rights Announcement' and references Article 26a of the WpHG (German Securities Trading Act). It explicitly states the total number of voting rights (131,684,776) as of August 2014. This type of announcement, detailing the total number of shares with voting rights, is a specific regulatory disclosure. It is not a full report (like 10-K or IR), nor is it a general dividend notice (DIV) or management change (MANG). It most closely aligns with a specific regulatory disclosure that doesn't fit the primary categories, making 'Regulatory Filings' (RNS) the most appropriate fallback, although it is highly specific. Given the options, 'RNS' serves as the best fit for a general regulatory disclosure not covered by the more specific codes like DVA (which is for *results* of a vote, not the total rights count) or SHA (which is for *changes* in capital structure, though voting rights are related). Since it is a direct regulatory disclosure about voting rights, RNS is the most suitable general regulatory category.
2014-08-29 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.